financetom
IXHL
financetom
/
Healthcare
/
IXHL
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Incannex Healthcare LimitedIXHL
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.

It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications.

The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.

It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.

In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials.

Incannex Hea

Latest News >
DOJ clears way for T-Mobile's $4.4 billion acquisition of UScellular
DOJ clears way for T-Mobile's $4.4 billion acquisition of UScellular
Jul 10, 2025
WASHINGTON (Reuters) -The U.S. antitrust enforcers greenlit T-Mobile's $4.4 billion acquisition of UScellular on Thursday, saying that while consolidation among cell carriers is concerning, UScellular customers would get more reliable service from the deal. Gail Slater, head of the U.S. Department of Justice's antitrust division, said in a statement that the DOJ is closing its investigation without seeking to block...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Canada's Hudbay Minerals suspends Snow Lake operations due to wildfire
Canada's Hudbay Minerals suspends Snow Lake operations due to wildfire
Jul 10, 2025
July 10 (Reuters) - Canadian copper miner Hudbay Minerals ( HBM ) said on Thursday it has temporarily suspended operations in Snow Lake due to a wildfire in Northern Manitoba. ...
Churchill Resources Raises $0.7 Million in a Private Placement of Shares
Churchill Resources Raises $0.7 Million in a Private Placement of Shares
Jul 10, 2025
05:06 PM EDT, 07/10/2025 (MT Newswires) -- Churchill Resources ( CRICF ) on Thursday said it closed a private placement of shares that raised $0.7 million. The company said it placed 14-million shares priced at $0.05 in the financing. Proceeds are earmarked for exploration of the company's properties and working capital. Churchill shares closed down $0.005 to$0.085 on the TSX...
Copyright 2023-2026 - www.financetom.com All Rights Reserved